Bionet (1784) - Net Assets
Based on the latest financial reports, Bionet (1784) has net assets worth NT$2.24 Billion TWD (≈ $70.67 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.10 Billion ≈ $97.62 Million USD) and total liabilities (NT$855.33 Million ≈ $26.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 1784 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.24 Billion |
| % of Total Assets | 72.39% |
| Annual Growth Rate | 8.29% |
| 5-Year Change | 85.84% |
| 10-Year Change | N/A |
| Growth Volatility | 16.17 |
Bionet - Net Assets Trend (2017–2024)
This chart illustrates how Bionet's net assets have evolved over time, based on quarterly financial data. Also explore Bionet assets under control for the complete picture of this company's asset base.
Annual Net Assets for Bionet (2017–2024)
The table below shows the annual net assets of Bionet from 2017 to 2024. For live valuation and market cap data, see 1784 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.40 Billion ≈ $75.48 Million |
+39.12% |
| 2023-12-31 | NT$1.72 Billion ≈ $54.26 Million |
+30.00% |
| 2022-12-31 | NT$1.32 Billion ≈ $41.74 Million |
+0.69% |
| 2021-12-31 | NT$1.32 Billion ≈ $41.45 Million |
+2.05% |
| 2020-12-31 | NT$1.29 Billion ≈ $40.62 Million |
-1.38% |
| 2019-12-31 | NT$1.31 Billion ≈ $41.19 Million |
-2.46% |
| 2018-12-31 | NT$1.34 Billion ≈ $42.22 Million |
-2.29% |
| 2017-12-31 | NT$1.37 Billion ≈ $43.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bionet's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1533.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$84.31 Million | 6.32% |
| Other Components | NT$1.25 Billion | 93.68% |
| Total Equity | NT$1.33 Billion | 100.00% |
Bionet Competitors by Market Cap
The table below lists competitors of Bionet ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TuHURA Biosciences Inc
NASDAQ:HURA
|
$115.08 Million |
|
Creepy Jar SA
WAR:CRJ
|
$115.10 Million |
|
ELK-Desa Resources Bhd
KLSE:5228
|
$115.13 Million |
|
Menang Corporation (Malaysia) Bhd
KLSE:1694
|
$115.20 Million |
|
Siam Pan Group PCL
BK:SPG
|
$115.06 Million |
|
ReFuels N.V.
OL:REFL
|
$115.06 Million |
|
Abra Information Technologies
TA:ABRA
|
$115.04 Million |
|
Bcl Industries Limited
NSE:BCLIND
|
$115.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bionet's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,187,631,000 to 1,334,627,000, a change of 146,996,000 (12.4%).
- Net income of 83,702,000 contributed positively to equity growth.
- Dividend payments of 33,153,000 reduced retained earnings.
- Share repurchases of 40,705,000 reduced equity.
- New share issuances of 13,994,000 increased equity.
- Other factors increased equity by 123,158,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$83.70 Million | +6.27% |
| Dividends Paid | NT$33.15 Million | -2.48% |
| Share Repurchases | NT$40.70 Million | -3.05% |
| Share Issuances | NT$13.99 Million | +1.05% |
| Other Changes | NT$123.16 Million | +9.23% |
| Total Change | NT$- | 12.38% |
Book Value vs Market Value Analysis
This analysis compares Bionet's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.22x to 2.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$22.52 | NT$72.60 | x |
| 2018-12-31 | NT$22.94 | NT$72.60 | x |
| 2019-12-31 | NT$22.49 | NT$72.60 | x |
| 2020-12-31 | NT$22.63 | NT$72.60 | x |
| 2021-12-31 | NT$23.03 | NT$72.60 | x |
| 2022-12-31 | NT$22.81 | NT$72.60 | x |
| 2023-12-31 | NT$25.09 | NT$72.60 | x |
| 2024-12-31 | NT$26.26 | NT$72.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bionet utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.27%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.85%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 2.36x
- Recent ROE (6.27%) is above the historical average (2.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -0.56% | -0.90% | 0.38x | 1.63x | NT$-118.02 Million |
| 2018 | 2.20% | 3.14% | 0.43x | 1.62x | NT$-85.84 Million |
| 2019 | 0.64% | 0.88% | 0.44x | 1.65x | NT$-99.98 Million |
| 2020 | 1.18% | 1.58% | 0.46x | 1.61x | NT$-94.94 Million |
| 2021 | 2.43% | 2.89% | 0.52x | 1.63x | NT$-83.12 Million |
| 2022 | 3.51% | 3.87% | 0.53x | 1.70x | NT$-70.15 Million |
| 2023 | 6.60% | 6.95% | 0.48x | 1.98x | NT$-40.36 Million |
| 2024 | 6.27% | 6.85% | 0.39x | 2.36x | NT$-49.76 Million |
Industry Comparison
This section compares Bionet's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $806,752,000
- Average return on equity (ROE) among peers: -33.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bionet (1784) | NT$2.24 Billion | -0.56% | 0.38x | $115.06 Million |
| DIVA Laboratories Ltd (4153) | $806.75 Million | -33.11% | 0.32x | $55.36 Million |
About Bionet
BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing… Read more